Role of Nivolumab in the Management of First-Line Unresectable Advanced or Recurrent Gastric Cancer in Combination with Chemotherapy: Lessons from the Japanese Experience

Recently, immune checkpoint inhibitor (ICI), such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies, has provided clinical benefits in various cancer types including advanced gastric cancer (AGC). Nivolumab, a monoclonal anti-PD-1 antibody, firstl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kubota, Yohei, Aoki, Yu, Kawazoe, Akihito, Shitara, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584771/
https://www.ncbi.nlm.nih.gov/pubmed/36275782
http://dx.doi.org/10.2147/CMAR.S351791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584771/
https://www.ncbi.nlm.nih.gov/pubmed/36275782
http://dx.doi.org/10.2147/CMAR.S351791

Ejemplares similares